Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $123,368 Project Grant on September 16, 2025, to The Research Foundation For The State University of New York (SUNY ESF) under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports research investigating the effects of structural racism on present-day disparities in environmental and social burdens as they relate to cardiovascular disease (CVD) outcomes through August 31,...
Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,894,767 Project Grant to the University of California, San Francisco (UCSF) on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the implementation, effectiveness, and cost-effectiveness of two implementation strategies for integrating a Community Health Worker (CHW)-facilitated hypertension telehealth intervention into routine primary health centers...
This $540,771 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to develop a personalized, socially-aware stroke risk stratification tool for patients with atrial fibrillation (AF). The primary objectives are to: Discover new stroke risk factors for AF patients, incorporating social determinants of health (SDOH) data. An innovative Poisson Binomial Comorbidity (PBC) framework will be used to...
Northwestern University received a $661,129 Project Grant from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on September 1, 2025, with completion targeted for June 30, 2030. The award supports the REACH-OUT Trial, an electronic health record (EHR)-based strategy designed to optimize blood pressure management among pregnancy-capable adults with hypertension in federally qualified health centers. The research addresses...
Grant Award Summary Brigham & Women's Hospital, Inc. received a $249,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective March 10, 2026 through February 28, 2029. The grant supports research investigating the mechanistic links between clonal hematopoiesis of indeterminate potential (CHIP) and coronary artery disease (CAD) through functional human genomic and multi-omics modifier...
DEEP IN THE HEART FOR WOMEN: Community-Engaged Intervention Study Award Overview Texas A&M Agrilife Research received a $538,998 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the "Deep in the Heart for Women" community-engaged intervention study in rural South Texas. Initiated September 1, 2025, and concluding June 30, 2029, this project delivers evidence-based, contextually...
The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pennsylvania a $692,846 Project Grant effective September 1, 2025, through June 30, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The Better Heart Study will deliver a randomized controlled trial with factorial design to evaluate the effectiveness of two behavioral science strategies aimed at increasing hypertension diagnosis and treatment uptake in Andhra Pradesh, India. The research...
Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $260,130 to The Regents of the University of California, San Francisco on July 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). This award supports the REMOTE-BP (Research and Mentorship for Optimizing Treatment and Evaluation of Blood Pressure) project, which complements the ongoing CHARMED (Comparing Hypertension Remote Monitoring Evaluation Redesign) clinical...
Federal Cooperative Agreement Award Summary The University of North Carolina at Chapel Hill received a $1,905,986 Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 30, 2025, with completion targeted for June 30, 2032. The PREEMPT (Prospective Randomized Evaluation and Management of Premature Atherosclerosis) study will develop and evaluate optimal strategies to screen for, identify,...
Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Ann & Robert H Lurie Children's Hospital of Chicago a $190,080 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for the period of September 5, 2025 through August 31, 2030. The award funds the development and pilot testing of Champion Fathers (Cardiovascular Health Assessment and Primary Care Coordination for Fathers), a cardiovascular health (CVH) screening and...
THE CARDIOVASCULAR HEALTH INNOVATION PROGRAM (CHIP) - THE RISK AND BURDEN OF CARDIOVASCULAR DISEASE (CVD) IS NOT EQUALLY SHARED. CVD IS THE LEADING CAUSE OF DEATH IN THE UNITED STATES AND NEW YORK CITY (NYC), AND PERSISTENT DISPARITIES IN PREVALENCE AND OUTCOMES HAVE ONLY WIDENED AMONG RACIAL AND ETHNIC GROUPS AND HISTORICALLY MARGINALIZED POPULATIONS. THESE DISPARITIES ARE CAUSED BY THE SOCIAL DETERMINANTS OF HEALTH (SDOH) AND INSTITUTIONAL RACISM. EFFECTIVE ACTION - INCREASING ACCESS TO RESOURCES FOR SOCIAL DETERMINANTS AND PROVEN EFFECTIVE PROGRAMS THAT HAVE BEEN TAILORED FOR THE COMMUNITY - REQUIRES INVESTING SPECIFICALLY IN HISTORICALLY DIS-INVESTED COMMUNITIES, INCREASING ACCESS TO EVIDENCE-BASED INTERVENTIONS, AND ADDRESSING THE SDOH. THE CARDIOVASCULAR HEALTH INNOVATION PROGRAM, REFERRED TO AS "CHIP", IS A NYC DEPARTMENT OF HEALTH AND MENTAL HYGIENE (DOHMH) PLACE-BASED INITIATIVE THAT TARGETS NYC HISTORICALLY MARGINALIZED POPULATIONS, PARTICULARLY BLACK POPULATIONS, AT GREATEST RISK FOR CVD AND RELATED POOR OUTCOMES, DEFINED THROUGH CENSUS TRACTS WITH PREVALENCE OF HYPERTENSION (HTN) GREATER THAN 53%. DOHMH WILL MAXIMIZE USE OF EXISTING PROGRAMS/SERVICES AND THROUGH TECHNICAL ASSISTANCE, TRAINING, COACHING, AND CONTRACTS FOR DIRECT SERVICE DELIVERY TO BUILD INFRASTRUCTURE, FILL THE GAPS TO IMPROVE AND PROMOTE EQUITY IN CVD OUTCOMES. USING A COLLECTIVE IMPACT APPROACH, DOHMH WILL PARTNER WITH 3 COMMUNITY AND 65 CLINICAL ORGANIZATIONS TO IMPLEMENT AN ARRAY OF EVIDENCED-BASED APPROACHES (I.E., OPTIMIZING/USING/ADVANCING ELECTRONIC HEALTH RECORDS [EHR]; HEALTH INFORMATION TECHNOLOGY [HIT]; GIS OR OTHER GEO-MAPPING TOOLS; TEAM-BASED CARE; SDOH SCREENING, REFERRAL, AND REFERRAL FOLLOW-UP; SELF-MEASURED BLOOD PRESSURE MONITORING WITH CLINICAL SUPPORT; CLINICAL-COMMUNITY LINKAGES; AND COMMUNITY HEALTH WORKERS) TO IDENTIFY, TRACK, AND ADDRESS AND/OR IMPROVE CVD CARE, OUTCOMES AND SDOH NEEDS. DOHMH WILL ALSO BUILD A DATA-DRIVEN AND ACTION-ORIENTED LEARNING COLLABORATIVE COMPRISED OF MULTIDISCIPLINARY STAKEHOLDERS TO SUPPORT IMPROVEMENT EFFORTS AND CONDUCT A RIGOROUS PROCESS AND OUTCOMES EVALUATIONS OF PROGRAM STRATEGIES. IN FIVE YEARS, CHIP WILL REACH NEARLY 261,118 ADULTS FROM THE POPULATION OF FOCUS. OVERALL HTN CONTROL WILL INCREASE BY OVER 17% (FROM 67.5% TO 79%). HTN CONTROL AMONG THE BLACK POPULATION WILL INCREASE ALMOST 25% (FROM 61.8% TO 76.9%). DISPARITIES IN HTN CONTROL BETWEEN THE TWO GROUPS WITH THE HIGHEST HTN CONTROL AT BASELINE, ASIAN (77.3%) AND WHITE (71.6%) ADULTS COMPARED TO BLACK (61.8%) ADULTS, WHO HAVE THE LOWEST RATE, WILL DECREASE BY 12.4% AND 6.7% POINTS, RESPECTIVELY. 7,605 ADULTS WILL BE REFERRED TO AND ACCESS SOCIAL SUPPORT SERVICES. ADDITIONALLY, CHIP WILL ACHIEVE THE FOLLOWING: ALL 65 CLINICS WILL HAVE POLICIES/PROTOCOLS IN PLACE REQUIRING THE USE OF EHRS AND STANDARDIZED CLINICAL QUALITY MEASURES TO TRACK HTN CONTROL MEASURES BY RACE, ETHNICITY, AND OTHER POPULATIONS OF FOCUS; 52 (80%) OF CLINICS WILL USE STANDARDIZED PROCESSES OR TOOLS TO IDENTIFY, ASSESS, TRACK, AND ADDRESS THE SOCIAL SERVICES SUPPORT NEEDS; ALL 65 CLINICS WILL HAVE POLICIES/PROTOCOLS IN PLACE REQUIRING THE USE OF CLINICAL DATA FROM EHRS OR HIT TO SUPPORT COMMUNICATION WITHIN THE CARE TEAM TO COORDINATE CARE FOR HTN AND HIGH CHOLESTEROL; 239,368 ADULTS WILL BE SERVED BY CLINICS THAT USE MULTIDISCIPLINARY CARE TEAMS THAT ADHERE TO EVIDENCE-BASED GUIDELINES; THERE WILL BE 3,050 SOCIAL SERVICES AND 222 TYPE OF SOCIAL SERVICES THAT ADDRESS SOCIAL NEEDS; 17,500 ADULTS WILL BE REFERRED TO LIFESTYLE CHANGE PROGRAMS OR SOCIAL SERVICES AND SUPPORT; 75 CHWS (OR THEIR EQUIVALENT) WILL ENGAGE WITH COMMUNITY ORGANIZATIONS TO PROVIDE A CONTINUUM OF CARE BY EXTENDING CLINICAL INTERVENTIONS AND ADDRESSING SOCIAL SERVICES AND SUPPORT NEEDS; AND 132,610 ADULTS WILL PARTICIPATE IN SELF-MEASURED BLOOD PRESSURE MONITORING WITH CLINICAL SUPPORT.